Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

B Cell Depletion and SARS‐CoV‐2 Vaccine Responses in Neuroimmunologic Patients
Barbara Kornek, Fritz Leutmezer, Paulus Rommer, et al.
Annals of Neurology (2022) Vol. 91, Iss. 3, pp. 342-352
Open Access | Times Cited: 36

Showing 26-50 of 36 citing articles:

Era of COVID-19 in Multiple Sclerosis Care
Jonathan D. Krett, Amber Salter, Scott D. Newsome
Neurologic Clinics (2023) Vol. 42, Iss. 1, pp. 319-340
Open Access | Times Cited: 3
Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study
Roberto Alfonso, Jerry Lin, Joyce Lei, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Long-Term Immune Response Profiles to SARS-CoV-2 Vaccination and Infection in People with Multiple Sclerosis on Anti-CD20 Therapy
Christina Woopen, Marie Dunsche, Georges Katoul Al Rahbani, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1464-1464
Open Access | Times Cited: 3
Literaturverzeichnis zum Titel: Zettl/Sieb: Diagnostik und Therapie neurologischer Erkrankungen, 6.A. 2024

Elsevier eBooks (2024), pp. e1-e123
Closed Access
Immunmediierte Erkrankungen des Nervensystems
Uwe K. Zettl, Jörn Peter Sieb
Elsevier eBooks (2024), pp. 47-109
Closed Access
The optimal interval before receiving SARS-COV-2 vaccination for patients who have received Anti-CD 20 monoclonal antibodies
Kexin Liu, Jinyu Li, Gaosi Xu
Virulence (2022) Vol. 13, Iss. 1, pp. 2012-2021
Open Access | Times Cited: 3
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
Markus Breu, Christian Lechner, Lisa Schneider, et al.
Pediatric Neurology (2023) Vol. 143, pp. 19-25
Open Access | Times Cited: 1
Humoral Response to SARS-CoV-2 Antigen in Patients Treated with Monoclonal Anti-CD20 Antibodies: It Is Not All about B Cell Recovery
Julia Feige, Klaus Berek, Michael Seiberl, et al.
Neurology International (2022) Vol. 14, Iss. 4, pp. 943-951
Open Access | Times Cited: 1
Ublituximab: A Novel Anti-CD20 Therapy for Multiple Sclerosis
Andrew B. Wolf, Enrique Álvarez
touchREVIEWS in Neurology (2022) Vol. 18, Iss. 2, pp. 117-117
Open Access | Times Cited: 1
Cross-direct effects in settings with two mediators
Erin E. Gabriel, Arvid Sjölander, Dean Follmann, et al.
Biostatistics (2022) Vol. 24, Iss. 4, pp. 1017-1030
Open Access
Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients
Jan Krejsek
Neurologie pro praxi (2022) Vol. 23, Iss. 6, pp. 488-491
Closed Access
Previous Page - Page 2

Scroll to top